Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Lymphoma, Large B-Cell, Diffuse

Lymphoma, B-Cell

Lymphoma, Non-Hodgkin

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphosarcoma

B-cell Lymphoma

Diffuse Large B-Cell Lymphoma

Bone Density Conservation Agents

Antineoplastic Agents

All Drugs and Chemicals

Tamoxifen

Estrogens

Estrogen Antagonists

Estrogen Receptor Antagonists

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

Estrogen Receptor Modulators

Selective Estrogen Receptor Modulators

DLBCL patients who achieve CR will be under follow up only

maintenance TAM 20 mg daily for DLBCL who achieve CR after chemotherapy and/or radiotherapy and/or BMT

Tamoxifen 20mg

the study aims to detect the benefit of maintenance tamoxifen after achieving CR with conventional immuno-chemotherapy and/or radiotherapy in patients with DLDCL

Diffuse large B-cell lymphoma (DLBCL) is the most common form of aggressive non-Hodgkin lymphoma. The standard immuno-chemotherapy (R-CHOP) markedly improves the prognosis of DLBCL, but up to 40% of patients still experience relapse or incomplete remission . So, there is a need for new targeted therapy for such malignancy. Recent studies identified a potential novel target in DLBCL, the ESR2 gene, which codes for the estrogen receptor beta (ERβ) protein, a receptor that can be targeted with selective ER modulators (SERMs) such as tamoxifen. Recent data shows that exposure of DLBCL cell lines to tamoxifen (either alone or in combination with CHOP chemotherapy) results in apoptosis and growth inhibition in vitro and in vivo. these data suggest the potential importance of ERβ in the pathogenesis of DLBCL as well as a potential role for tamoxifen in the treatment of DLBCL.50-100 patients with newly diagnosed DLBCL will be treated with standard immuno-chemotherapy according to disease stage with detection of ERB and ERA on the tissue samples using IHC. After the end of chemotherapy treatment patients who achieve CR will be randomized to either receive tamoxifen maintenance (20 mg daily) versus follow up to evaluate possible tamoxifen effect on disease recurrence, DFS and OS.

PT who achieve CR after 2nd line chemotherapy versus post BMT will also be recruited.

Maintenance Hormonal Therapy and DLBCL

Effect of Maintenance Hormonal Therapy on the Outcome of Patients With DLBCL

the period from 1st diagnosis till study end or death

if there is any increase in adverse events while on TAM maintenance

Sohag University

lecturer of clinical oncology

Symptoms and General Pathology

Digestive System Diseases

Cysts

Pancreatic Cyst

Neoplasms, Cystic, Mucinous, and Serous

Pancreatic Diseases

Gastrointestinal Diseases

Neoplasms, Glandular and Epithelial

Gastrointestinal Agents

Pancrelipase

Pancreatin

Tamoxifen 20mg by mouth daily for up to 6 months

Tamoxifen is a nonsteroidal antiestrogen for oral administration.

Peggy Heires, BA

Christina Hoy, DNP

Kelsey Klute, MD

This is an open-label pilot study of tamoxifen as chemoprevention in patients with pancreatic MCN who will not undergo immediate resection. Up to 15 subjects will be enrolled and take tamoxifen 20mg by mouth daily for up to 24 weeks.

This is an open-label pilot study of tamoxifen as chemoprevention in patients with pancreatic MCN who will not undergo immediate resection. Up to 15 subjects will be enrolled and take tamoxifen 20mg by mouth daily for up to 24 weeks. The primary endpoints are feasibility of tamoxifen as chemoprevention in patients with pancreatic MCN and objective response rate as assessed by MRI. This study is intended to inform the design of a subsequent trial formally powered to detect the benefit of tamoxifen in treating pancreatic MCN.

The clinical features of pancreatic MCN support the influence of sex hormones in the pathogenesis of the disease. Anti-hormonal therapy may therefore constitute an effective approach to treatment of MCN and chemoprevention of pancreatic adenocarcinoma. Preliminary analyses from preclinical studies suggest that tamoxifen inhibits proliferation and apoptosis in MCN epithelial cells and fibroblasts. We hypothesize that in humans, treatment with tamoxifen will lead to cyst regression or stabilization and may spare or delay the need for resection.

Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection

A Pilot Study of Chemoprevention With Tamoxifen in Patients With Pre-Invasive Pancreas Mucinous Cystic Neoplasms Who Will Not Undergo Immediate Resection

Adherence rate, defined as the proportion of subjects who take ≥70% of the prescribed tamoxifen doses with adherence at least 60%, meaning ≥60% of subjects take ≥70% of the prescribed tamoxifen doses

Retention rate, defined as the proportion of subjects who complete imaging and study procedures at the 6-month visit with retention of at least 50%, meaning at least 50% of subjects complete imaging and study procedures at the 6-month visit

The ORR will be estimated based on the proportion of subjects with complete or partial response on MRI/MRCP; partial response is defined by ≥ 20% decrease in maximal cyst diameter.

University of Nebraska

Skin and Connective Tissue Diseases

Breast Neoplasms

Breast Diseases

Skin Diseases

Reproductive Control Agents

Letrozole

Mitogens

Goserelin

Anastrozole

Triptorelin Pamoate

Aromatase Inhibitors

Enzyme Inhibitors

Contraceptive Agents

Contraceptive Agents, Female

Contraceptive Agents, Hormonal

premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer T4 Nany or Tany N2-3

postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer T4 Nany or Tany N2-3

Anastrozole 1mg

Letrozole 2.5mg

Gonadotropin Releasing Hormone (GnRH) agonist

Triptorelin

Artamonova Elena

Elena Kovalenko

Tatiana Titova

Kovalenko Elena

Titova Tatiana

Neoadjuvant Endocrine Therapy for pre- and postmenopausal women with T4 Nany or TanyN2-3 estrogen receptor (ER) -positive, progrsteron receptor (PR) -positive and HER2 negative breast cancer. Real Clinical Practice in Russia.

Neoadjuvant Endocrine Therapy for pre- and postmenopausal women with T4 Nany or TanyN2-3 estrogen receptor (ER) -positive, progrsteron receptor (PR) -positive and HER2 negative breast cancer. Real Clinical Practice in Russia.

Nonrandomized, retrospective clincal trial

Eligible postmenopausal women were treated with tamoxifen 20 mg, exemestane 25 mg daily, letrozole 2.5 mg daily, or anastrozole 1 mg daily before surgery

or

Eligible premenopausal women were treated with tamoxifen 20 mg, exemestane 25 mg daily, letrozole 2.5 mg daily, or anastrozole 1 mg daily in combination with ovarian suppression before surgery

Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia

Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia.

Residual cancer burden (RCB) is estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. 6 variables are included in a calculation formula.

the preoperative endocrine prognostic index (PEPI)- consisting of the pathological tumor size, pathological node status, Ki67 labeling index, and ER status of residual tumors after NAE

DFS event is defined as the evidence of local and/or distant recurrence, new primary breast tumour, or death from any cause.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Maintenance Hormonal Therapy and DLBCL	NCT06355401	Diffuse Large B...	Tamoxifen 20mg	18 Years - 75 Years	Sohag University
Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection	NCT06320990	Pancreatic Cyst Pancreatic Muci...	Tamoxifen 20mg	19 Years -	University of Nebraska
Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia	NCT05800197	Breast Cancer Neoadjuvant End...	Tamoxifen 20mg Anastrozole 1mg Letrozole 2.5mg Goserelin Triptorelin	18 Years -	Blokhin's Russian Cancer Research Center
Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection	NCT06320990	Pancreatic Cyst Pancreatic Muci...	Tamoxifen 20mg	19 Years -	University of Nebraska
Maintenance Hormonal Therapy and DLBCL	NCT06355401	Diffuse Large B...	Tamoxifen 20mg	18 Years - 75 Years	Sohag University

Spots Global Cancer Trial Database for tamoxifen 20mg